ARTEMIDE-Lung04: A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab Monotherapy for the First-line Treatment of Patients with PD-L1-high Metastatic Non-small Cell Lung Cancer (D702GC00001)

For more information about this clinical trial, please visit the following link: https://clinicaltrials.gov/study/NCT06868277?term=artemide-lung04&limit=10&sort=@relevance&rank=1

Contact name

Laura Morse Cucci

Clinical trials study type

Oncology - Pulmonary

Clinical trials trial status

Open to Accrual

IRB number

2270783

Principal investigator

Mei Tang, MD

Clinical trials study number

G2501

Phone

443-849-3122

Clinical trials title (full)

ARTEMIDE-Lung04: A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab Monotherapy for the First-line Treatment of Patients with PD-L1-high Metastatic Non-small Cell Lung Cancer (D702GC00001)